Keywords: Azur Pharma, Jazz Pharmaceuticals, All-stock merger
Azur Pharma agrees to all-stock merger with Jazz Pharma to create firm with $474 million revenues
Article | 20 September 2011
USA-based drugmaker Jazz Pharmaceuticals (Nasdaq: JAZZ) and privately-held Azur Pharma have agreed to combine in an all-stock transaction that creates ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
